Teduglutide in short bowel syndrome patients: A way back to normal life?
Quick Facts
What This Study Found
All 13 patients (100%) showed a clinically significant reduction in parenteral support volume.
Key Numbers
How They Did This
A retrospective analysis of 13 patients treated with teduglutide in a specialized program over four years.
Why This Research Matters
This research highlights the potential of teduglutide to improve the quality of life for patients with short bowel syndrome, reducing reliance on parenteral nutrition.
What This Study Doesn't Tell Us
The study is limited by its small sample size and retrospective design, which may affect the generalizability of the findings.
Trust & Context
- Original Title:
- Teduglutide in short bowel syndrome patients: A way back to normal life?
- Published In:
- JPEN. Journal of parenteral and enteral nutrition, 46(2), 300-309 (2022)
- Authors:
- Harpain, Felix, Schlager, Lukas, Hütterer, Elisabeth, Dawoud, Christopher, Kirchnawy, Sabine, Stift, Judith, Krotka, Pavla, Stift, Anton
- Database ID:
- RPEP-06170
Evidence Hierarchy
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-06170APA
Harpain, Felix; Schlager, Lukas; Hütterer, Elisabeth; Dawoud, Christopher; Kirchnawy, Sabine; Stift, Judith; Krotka, Pavla; Stift, Anton. (2022). Teduglutide in short bowel syndrome patients: A way back to normal life?. JPEN. Journal of parenteral and enteral nutrition, 46(2), 300-309. https://doi.org/10.1002/jpen.2272
MLA
Harpain, Felix, et al. "Teduglutide in short bowel syndrome patients: A way back to normal life?." JPEN. Journal of parenteral and enteral nutrition, 2022. https://doi.org/10.1002/jpen.2272
RethinkPeptides
RethinkPeptides Research Database. "Teduglutide in short bowel syndrome patients: A way back to ..." RPEP-06170. Retrieved from https://rethinkpeptides.com/research/harpain-2022-teduglutide-in-short-bowel
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.